We are live on ! Find out more
WP

Woodline Partners Portfolio holdings

AUM $26.4B
1-Year Est. Return 44.85%
This Fund
S&P 500
This Quarter Est. Return
+32.2%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
AUM
$2.52B
AUM Growth
+$1.12B
Cap. Flow
+$772M
Cap. Flow %
30.59%
Top 10 Hldgs %
26.22%
Holding
205
New
69
Increased
52
Reduced
26
Closed
58

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$62.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$61M
3
FIS icon
Fidelity National Information Services
FIS
+$54.2M
4
KLAC icon
KLA
KLAC
+$44.1M
5
PYPL icon
PayPal
PYPL
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 46.91%
2 Technology 35.52%
3 Communication Services 5.66%
4 Consumer Discretionary 4.26%
5 Industrials 2.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NATI
201
DELISTED
National Instruments Corp
NATI
-223,926
Closed -$7.41M
HARP
202
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
-7,894
Closed -$914K
CHNG
203
DELISTED
Change Healthcare Inc. Common Stock
CHNG
-323,806
Closed -$3.23M
GLUU
204
DELISTED
Glu Mobile Inc.
GLUU
-882,935
Closed -$5.55M
TECD
205
DELISTED
Tech Data Corp
TECD
-5,702
Closed -$746K

Similar funds

Woodline Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Woodline Partners held 205 positions worth $2.52B, up 80% from $1.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Woodline Partners deployed $772M of net new capital in Q2 2020, opening 69 new positions and adding to 52 existing holdings. Its largest new stake was Johnson & Johnson: 418,880 shares worth $58.9M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $41.2M trimmed.

  • Woodline Partners's largest Q2 2020 buy was Johnson & Johnson: 418,880 shares worth $58.9M.
  • Woodline Partners added most to Intel in Q2 2020, an estimated $62.5M increase.
  • Woodline Partners's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $41.2M.
  • Woodline Partners fully exited Pfizer in Q2 2020, selling an estimated $65.7M.
  • Woodline Partners's ten largest holdings make up 26% of its $2.52B portfolio in Q2 2020.
  • Woodline Partners opened 69 new positions and closed 58 in Q2 2020.
  • Woodline Partners's portfolio value rose 80% quarter-over-quarter to $2.52B.

Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.